# US 2026/0284234 A1 · Isoindolinone compounds and imaging agents for imaging huntingtin protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0284234 A1
- Document ID: US20260284234A1
- Status: Published application
- Kind: A1
- Application number: 19/667,319
- Filed: 2026-05-04
- Published: 2026-09-24
- Earliest claimed: 2021-04-08
- Assignees: CHDI Foundation, Inc.
- Applicants: CHDI Foundation, Inc.
- Inventors: Longbin Liu; Celia Dominguez; Jonathan Bard; Christopher John Brown; Xuemei Chen; Daniel Clark-Frew; Matthew Robert Mills; Peter David Johnson; Elise Gadouleau
- Web page: https://patentgrep.com/patent/US20260284234A1

## CPC

- A61K 51/0459: {having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine}
- A61K 51/0455: {having six-membered rings with one nitrogen as the only ring hetero atom}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 401/14: containing three or more hetero rings
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Provided herein are certain isoindolinone compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.

## Claims

### Claim 1

A compound that is:
or an isotopically enriched analog, pharmaceutically acceptable salt, tautomer, stereoisomer, or a mixture of stereoisomers thereof, optionally wherein the compound is labeled with a radioactive isotope.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is labeled with a radioactive isotope.

### Claim 3 (depends on 2)

The compound of claim 2, wherein the compound contains a positron-emitting radioactive isotope selected from 11C, 13N, 15O, and 18F.

### Claim 4 (depends on 2)

An imaging agent comprising the compound of claim 2, or an isotopically enriched analog, pharmaceutically acceptable salt, tautomer, stereoisomer, or a mixture of stereoisomers thereof.

### Claim 5 (depends on 4)

A method of detecting a presence or absence of a protein susceptible to aggregation in an individual comprising administering an effective amount of the imaging agent of claim 4 to the individual, and generating an image of a body part or body area of the individual.

### Claim 6 (depends on 5)

The method of claim 5, wherein the presence or absence of a protein aggregate corresponds to a presence or absence of a neurodegenerative disease.

### Claim 7 (depends on 6)

The method of claim 6, wherein the neurodegenerative disease is selected from Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, Prion disease, and spinocerebellar ataxias.

### Claim 8 (depends on 7)

The method of claim 7, wherein the neurodegenerative disease is Huntington's disease (HD).

### Claim 9 (depends on 5)

The method of claim 5, wherein generating an image comprises positron emission tomography (PET) imaging, PET with concurrent computed tomography imaging (PET/CT), PET with concurrent magnetic resonance imaging (PET/MRI), single-photon emission computed tomography (SPECT) imaging, or a combination thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein generating an image comprises PET imaging.
